If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
349
results.
Updated on
14/09/2026 [08:02:00]
Results 200 to 225 of 349
Absstract of: WO2026165098A1
A method for modulating splicing of Sirtuin 1 includes administering or adding to a subject 3-methyl-1-phenyl-2-pyrazolin-5-one, a physiologically acceptable salt thereof, a hydrate thereof, and/or a solvate thereof.
Absstract of: WO2026165222A2
The invention features methods of treating a subject having a disorder by administering to the subject a kisspeptin analog or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Disorders that may be treated by the kisspeptin analogs or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition include reproductive disorders, hypoactive sexual arousal disorder, respiratory diseases, metabolic disorders, liver disorders, bone disorders, VMS, neurodegenerative disorders, and sequelae of neurotropic viruses. Also provided herein are methods of identifying a subject as having congenital hypogonadotropic hypogonadism (HH) and methods of determining whether a patient having a disorder is likely to respond to a therapy comprising a therapeutically effective amount of a kisspeptin analog or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
Absstract of: US20260226172A1
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
Absstract of: US20260227412A1
The present invention provides for the use of IFN-I activity as a predictive biomarker for the treatment of patients with toll-like receptor (TLR) inhibitors and related uses and methods.
Absstract of: US20260229316A1
Embodiments herein describe systems and methods to generate a risk score for an individual to develop postoperative neurocognitive disorder (POND). Various embodiments obtain multi-omics data from an individual, such as genomics, transcriptomics, and proteomics. In certain embodiments, a machine learning algorithm is used to generate the risk score based on the multi-omics data. In further embodiments, clinical data is further used in the determination of the risk score.
Absstract of: WO2026164954A1
The presently claimed and described technology provides a calibrator dipeptide for use in immunoassay methods for detecting phosphorylated tau (p-tau)217.
Absstract of: WO2026165496A1
The invention relates to methods of altering expression or activity of NOVA 1 or NOVA2. The invention provides anti-microRNA molecules directed against miRNA binding sites on untranslated regions that serve to redirect RNA translation, including acting as a competitor for miRNA binding on targets, including NOVA1 and NOVA2. The invention provides methods for inhibiting microRNAs directed to NOVA1 or NOVA 1 in an animal by administering one of more anti-microRNA molecule specific therefore. Methods of alleviating one or more disease or condition, including altering or modulating vocalization, language dysfunction, autism (including non-verbal autism), microencephaly, seizures, developmental delay or cancer are provided. In accordance with such methods, NOVA1 or NOVA2 expression or activity is modulated to result in alleviation of one or more disease or condition.
Absstract of: WO2026165436A1
Methods are provided for the capture of misfolded protein aggregates by beads bound to an amyloid-binding dye. Methods for using the misfolded protein aggregate-bound beads are also provided.
Absstract of: WO2026162924A1
The disclosure relates to a device for measuring liquid viscosity wherein said device comprises a concave reservoir configured to hold a volume of liquid and one or more wells extending from an opening disposed at the base of said reservoir, wherein said base comprises an aperture having dimensions configured to retain within said well a liquid having a viscosity at or above a specific threshold viscosity by surface tension, but permit a liquid having a viscosity below said specific threshold viscosity to pass through said well under the influence of gravity. Further, the invention also relates to a method for assessing liquid viscosity using the abovementioned device, particularly in individuals suffering from dysphagia in healthcare facilities, such as care homes.
Absstract of: US20260226173A1
The present technology relates generally to compositions that specifically recognize and bind to a WT-1 peptide complexed with a major histocompatibility antigen (e.g., HL A-A*02). The compositions of the present technology are useful in methods for treating WT-1-associated diseases (e.g., cancers) in a subject in need thereof.
Absstract of: US20260224661A1
Methods are provided for enhancing synaptogenesis. It is shown herein that the receptor for the circulating factor SPARCL1 (secreted protein acidic and rich in cysteine-like protein) are teneurin proteins (Tenm1-4). The binding site for SPARCL1 is localized to domain 3, which specifically binds to the C terminal domain of SPARCL1 (SPARCL1-C). Contacting neuronal cells expressing a teneurin protein with SPARC is sufficient to increase synapse formation on the neuronal cells.
Absstract of: US20260224206A1
An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.
Absstract of: EP4785940A1
0001 The present invention relates to pharmaceutical combinations, pharmaceutical compositions, kits comprising a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and a TNFα-inhibitor. The present invention also relates to said pharmaceutical combinations for use in the treatment of an inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula:
Absstract of: EP4786984A1
The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.
Absstract of: EP4786977A1
A method for identifying biomarkers of a health condition, comprising: providing a first neuronal circuit with neuronal cells from a first individual organism on a multi-electrode array, applying stimuli to the circuit, obtaining electrophysiological recordings, deriving cell-level and/or circuit-level features from the recordings, associating derived features with presence or absence of the health condition, comparing associated data with reference data, and determining if reference features or derived features are biomarkers for the condition.
Absstract of: WO2025160022A1
The presently claimed and described technology provides methods for chemiluminescence-based assays for detecting phosphorylated tau (p-tau)217 in a biological sample employing 1,2 dioxetane compounds.
Absstract of: TW202542522A
Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.
Absstract of: CN122503499A
本发明涉及生物医药技术领域，尤其是涉及基于LTF的PASC相关心血管系统症状风险评估应用。本发明提供了一种以LTF为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Absstract of: CN122506168A
本发明公开了一种基于金纳米颗粒的等离子增强荧光偶联适配体比率传感器的制备方法及其在淀粉样蛋白可视化检测中的应用。本发明制备金纳米颗粒，通过加入EDC/NHS将金纳米颗粒固定在氨基化的酶标板上；使两端分别修饰氨基和巯基的β‑淀粉样蛋白适配体形成Au‑S键接枝至金纳米颗粒修饰的酶标板；加入EDC/NHS将孟加拉玫瑰通过酰胺键接枝至金纳米颗粒上的适配体上得到以等离子体增强荧光偶联适配体作为响应荧光探针，以9‑蒽甲酸作为参比荧光制得等离子增强/比率荧光探针传感器。本发明制备的等离子增强/比率荧光探针传感器的稳定性好，实现便携式、超灵敏和特异性的β‑淀粉样蛋白可视化定量检测。
Absstract of: CN122506155A
该水产品组胺的快速检测试纸条制备及检测方法，通过测流层析的方式，以适配体为特异性识别元件，使用价格适宜、易于合成的DNA链作为基本元件解决了现有水产品组胺的检测方法存有的操作过程繁琐、特异性和稳定性弱、成本高昂的问题，特别适合水产品组胺检测使用的需要。
Absstract of: WO2025101131A1
The invention relates generally to cellular biology. In particular, the specification teaches a method of detecting and quantifying cellular biological age of a cell.
Absstract of: WO2026162642A1
The current invention refers to a in vivo method for identifying the risk of an individual of suffering from a periodontal disease, comprising detecting the FUT2 gen genotype and/or the phenotype associated to the secretor status of the Lewis B antigen from a biological sample of said individual.
Absstract of: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Absstract of: CN122483194A
本申请涉及生物医药的技术领域，具体涉及一种靶向APOE蛋白HSPG结合区的单克隆抗体或其抗原结合片段、及其应用。该单克隆抗体或其抗原结合片段包括重链可变区和轻链可变区；重链可变区包括重链互补决定区CDRH1（SEQ ID NO:3）、CDRH2（SEQ ID NO:4）以及CDRH3（SEQ ID NO:5）；轻链可变区包括轻链互补决定区CDRL1（SEQ ID NO:6）、CDRL2（SEQ ID NO:7）以及CDRL3（SEQ ID NO:8）。本申请的单克隆抗体通过特异性阻断APOE与HSPG的病理性相互作用，为阿尔茨海默病等神经退行性疾病提供了一种全新的治疗策略。
Nº publicación: CN122487683A 31/07/2026
Applicant:
浙江格物致知生物科技有限公司
Absstract of: CN122487683A
0001 本发明公开了一种用于阿尔茨海默病的联检试剂盒及其应用，属于医学诊断技术领域。该试剂盒包括检测神经颗粒蛋白（NRGN）的第一检测试剂、检测β‑淀粉样蛋白42（Aβ42）的第二检测试剂和检测磷酸化tau蛋白217（p‑tau217）的第三检测试剂。本发明通过联合检测NRGN、Aβ42和p‑tau217三种标志物的水平，并依据NRGN<100 pg/mL、Aβ42<800 pg/mL、p‑tau217>0.5 pg/mL的判定规则进行综合评估，能够显著提高阿尔茨海默病诊断的灵敏度（95.8%）和特异性（92.2%），ROC曲线下面积AUC达0.956，优于任一单一标志物。本发明试剂盒以外周血、尿液和脑脊液为检测样本，无创、便捷、成本可控，适用于阿尔茨海默病的大规模筛查及临床辅助诊断。
BOPI
Electronic site
